Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
Adcirca

Adcirca

Phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH).

OverviewStructured DataIssuesContributorsActivity

All edits

Edits on 22 Feb, 2022
Vitalii Mazuryk profile picture
Vitalii Mazuryk
edited on 22 Feb, 2022
Edits made to:
Infobox (+1 properties)
Description (+107 characters)
Article (+380 characters)
Topic thumbnail

Adcirca

Phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH).

Article

Adcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).

Infobox
Industry
Medicine
Medicine
Edits on 17 Feb, 2022
"update inverses"
Golden AI profile picture
Golden AI
edited on 17 Feb, 2022
Edits made to:
Infobox (+1 properties)
Infobox
Product parent company
United Therapeutics Corp.
United Therapeutics Corp.
"Created via: Web app"
Vitalii Mazuryk profile picture
Vitalii Mazuryk
created this topic on 17 Feb, 2022
Edits made to:
Infobox (+2 properties)
Topic thumbnail

 Adcirca

Phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH).

Infobox
Is a
Product
Product
Website
https://www.adcirca.com/patient/index.aspx

Find more entities like Adcirca

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.